What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Immune system
- Cancer
His primary areas of study are Immunology, Mycobacterium tuberculosis, Tuberculosis, Latent tuberculosis and Granuloma.
His Immunology research includes themes of Pneumococcal conjugate vaccine, Streptococcus pneumoniae and Pneumococcal infections.
His research ties Cytokine and Mycobacterium tuberculosis together.
His Tuberculosis study combines topics in areas such as Antigen and Immunity.
His research integrates issues of Macrophage, Isoniazid, Disease and Virology in his study of Latent tuberculosis.
His work carried out in the field of Granuloma brings together such families of science as Tumor necrosis factor alpha and Interferon gamma.
His most cited work include:
- SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. (901 citations)
- SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. (901 citations)
- Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. (376 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Tuberculosis, Immunology, Mycobacterium tuberculosis, Virology and Immune system.
His Tuberculosis study integrates concerns from other disciplines, such as T cell, Immunity, Lung, Disease and Granuloma.
In his research on the topic of Immunology, Spleen is strongly related with Bronchoalveolar lavage.
His research in Mycobacterium tuberculosis is mostly concerned with Latent tuberculosis.
Philana Ling Lin interconnects Acquired immune system and Lymph in the investigation of issues within Virology.
His Immune system research integrates issues from Antibody, Avidity and Lymph node.
He most often published in these fields:
- Tuberculosis (59.09%)
- Immunology (57.27%)
- Mycobacterium tuberculosis (50.91%)
What were the highlights of his more recent work (between 2018-2021)?
- Tuberculosis (59.09%)
- Mycobacterium tuberculosis (50.91%)
- Immunology (57.27%)
In recent papers he was focusing on the following fields of study:
Philana Ling Lin focuses on Tuberculosis, Mycobacterium tuberculosis, Immunology, Immune system and Cytotoxic T cell.
His research in Tuberculosis intersects with topics in Multiple pathologies, Disease, Antibiotic exposure, Molecular imaging and Human pathogen.
He focuses mostly in the field of Mycobacterium tuberculosis, narrowing it down to matters related to CD8 and, in some cases, Heterologous, Adjuvant, Cytokine and Peripheral blood mononuclear cell.
His Immunology research focuses on Immunity in particular.
He studied Immune system and Granuloma that intersect with Interleukin 4.
His T cell research incorporates elements of Latent tuberculosis, Simian immunodeficiency virus and Virology.
Between 2018 and 2021, his most popular works were:
- SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. (901 citations)
- SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. (901 citations)
- Prevention of tuberculosis in macaques after intravenous BCG immunization. (130 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Immune system
- Cancer
Philana Ling Lin spends much of his time researching Lung injury, Cell biology, Interferon-stimulated gene, Downregulation and upregulation and Interferon.
His Lung injury research includes elements of Proteases, Cell culture and Single-cell analysis.
His research on Cell biology often connects related topics like Receptor.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
